Clinical experience with BCG immune prevention in superficial bladder cancer
Bach, D.; Romics, I.; Rüssel, C.
Der Urologe. Ausg. a 31(5): 296-301
1992
ISSN/ISBN: 0340-2592 PMID: 1302409 Document Number: 399887
Previous randomized studies have shown that in cases of superficial urothelial carcinoma or carcinoma in situ of the urinary bladder, complete and long-lasting remission can be obtained by immunotherapy with bacillus Calmette-Guérin (BCG). Such studies have shown that BCG reduces the recurrence rate significantly compared with transurethral resection alone. Our 6-year experience with BCG Pasteur strain (and Connaught strain, respectively) in tumour stages pTis, pTa and pT1 (G I-II) shows lasting remission in 88.5% (73%) of 78 (26) patients after transurethral resection of the tumour. A complete remission was found in 92% of patients with carcinoma in situ (12 patients). The local and the rare systemic side effects were all of limited duration, tolerable, easily treated and fully reversible.
Document emailed within 1 workday
